Timothy S. Chang, MD, PhD and Lisa L. Barnes, PhD, discuss health disparities in Alzheimer disease and related dementias and how to improve clinical outcomes for patients from underrepresented groups.
Although an estimated 82 million people worldwide will be affected by dementia by 2030, research demonstrates that cognitive decline often goes unrecognized in primary care settings.
Administering a visual association test in patients with a small decline on the Mini-Mental State Examination during a 2-year period has substantial incremental value for identifying those at elevated risk for developing dementia.
In a large population-based study, individuals with sustained hypertension in midlife to late life had a 49% increased risk of subsequent dementia compared with those who remained normotensive.
Anticholinergic drugs for depression, urologic conditions, or Parkinson disease are associated with potential dementia occurrences up to 20 years after drug exposure.